Although we were not able to identify a singular origin for multimeric sICs, our data clearly show their presence in COVID-19 patients with an increase in FcγRIIIA/CD16A-reactive sICs corresponding with severity of disease reaching activation levels comparable to those observed in SLE patients with active disease. This evidence concerns the gene FCGR3A and systemic lupus erythematosus.